Evidence map›Paper›PMID 34373860›Full record

ArticlemedRxiv : the preprint server for health sciences2021

Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals.

Kenji Maeda, Masayuki Amano, Yukari Uemura, Kiyoto Tsuchiya, Tomoko Matsushima, Kenta Noda, Yosuke Shimizu, Asuka Fujiwara, Yuki Takamatsu, Yasuko Ichikawa and 12 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 9 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 2 countries.

Kenji MaedaDepartment of Refractory Viral Infections, National Center for Global Health and Medicine (NCGM) Research Institute, Tokyo, Japan.
Masayuki AmanoDepartment of Clinical Sciences, Kumamoto University Hospital, Kumamoto, Japan.
Yukari UemuraDepartment of Clinical Sciences, NCGM, Tokyo, Japan.
Kiyoto TsuchiyaAIDS Clinical Center, NCGM, Tokyo, Japan.
Tomoko MatsushimaSysmex Corporation, Hyogo, Japan.
Kenta NodaSysmex Corporation, Hyogo, Japan.
Yosuke ShimizuDepartment of Clinical Sciences, NCGM, Tokyo, Japan.
Asuka FujiwaraDepartment of Refractory Viral Infections, National Center for Global Health and Medicine (NCGM) Research Institute, Tokyo, Japan.
Yuki TakamatsuDepartment of Refractory Viral Infections, National Center for Global Health and Medicine (NCGM) Research Institute, Tokyo, Japan.
Yasuko IchikawaJCHO Kumamoto General Hospital, Kumamoto, Japan.
Hidehiro NishimuraJCHO Kumamoto General Hospital, Kumamoto, Japan.
Mari KinoshitaJCHO Kumamoto General Hospital, Kumamoto, Japan.
Shota MatsumotoJCHO Kumamoto General Hospital, Kumamoto, Japan.
Hiroyuki GatanagaAIDS Clinical Center, NCGM, Tokyo, Japan.
Kazuhisa YoshimuraTokyo Metropolitan Institute for Public Health, Tokyo, Japan.
Shin-Ichi OkaAIDS Clinical Center, NCGM, Tokyo, Japan.
Ayako MikamiDepartment of Clinical Sciences, NCGM, Tokyo, Japan.
Wataru SugiuraDepartment of Clinical Sciences, NCGM, Tokyo, Japan.
Toshiyuki SatoSysmex Corporation, Hyogo, Japan.
Tomokazu YoshidaSysmex Corporation, Hyogo, Japan.
Shinya ShimadaJCHO Kumamoto General Hospital, Kumamoto, Japan.
Hiroaki MitsuyaDepartment of Refractory Viral Infections, National Center for Global Health and Medicine (NCGM) Research Institute, Tokyo, Japan.
Kumamoto Medical Center · JPSysmex (Japan) · JPNational Center for Global Health and Medicine · JPKumamoto University Hospital · JPNational Institutes of Health · USTokyo Metropolitan Institute of Public Health · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile mRNA vaccines against SARS-CoV-2 have been exceedingly effective in preventing symptomatic viral infection, the features of immune response remain to be clarified.

methodsIn the present prospective observational study, 225 healthy individuals in Kumamoto General Hospital, Japan, who received two BNT162b2 doses in February 2021, were enrolled. Correlates of BNT162b2-elicited SARS-CoV-2-neutralizing activity (50% neutralization titer: NT

findingsSignificant rise in NT

interpretationBNT162b2-elicited immune response has no significant association with AEs. BNT162b2-efficacy is likely diminished to under detection limit by 6-7 months post-1st shot. High-level neutralizing antibody-containing serums potently to moderately block the infection of SARS-CoV-2 variants; however, a few moderate-level neutralizing antibody-containing serums failed to do so. If BNT162b2-elicited immunity memory is short, an additional vaccine or other protective measures would be needed. RESEARCH IN CONTEXT:

Identifiers

PMID34373860
PMCPMC8351777
OpenAlexW3188625625

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.